Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 95

Ono Pharmaceutical Co., Ltd. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Ono Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011” provides data on the Ono Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ono Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ono Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Ono Pharmaceutical Co., Ltd. - Brief Ono Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ono Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ono Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ono Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Ono Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ono Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ono Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ono Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ono Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Ono Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd. - Key Therapeutics; Ono Pharmaceutical Co., Ltd. - Pipeline Overview and Promising Molecules; Ono Pharmaceutical Co., Ltd. - News; Ono Pharmaceutical Co., Ltd. - Latest Updates; Ono Pharmaceutical Co., Ltd. - Pipeline; Ono Pharmaceutical Co., Ltd. - Discontinued/Dormant Projects

List of Tables
List of Figures
Ono Pharmaceutical Co., Ltd. Snapshot
Ono Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Ono Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Ono Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Ono Pharmaceutical Co., Ltd. – Pipeline Products Glance
Ono Pharmaceutical Co., Ltd. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Ono Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ono Pharmaceutical Co., Ltd. – Drug Profiles
Asimadoline
Product Description
Mechanism of Action
R&D Progress
Cereact
Product Description
Mechanism of Action
R&D Progress
CNS 7056
Product Description
Mechanism of Action
R&D Progress
ONO 6950
Product Description
Mechanism of Action
R&D Progress
ONO-2952
Product Description
Mechanism of Action
R&D Progress
ONO-3849
Product Description
Mechanism of Action
R&D Progress
ONO-4053
Product Description
Mechanism of Action
R&D Progress
ONO-5334
Product Description
Mechanism of Action
R&D Progress
ONO-7746
Product Description
Mechanism of Action
R&D Progress
ONO-8539
Product Description
Mechanism of Action
R&D Progress
ONX 0912
Product Description
Mechanism of Action
R&D Progress
Proemend
Product Description
Mechanism of Action
R&D Progress
Ono Pharmaceutical Co., Ltd. – Pipeline Analysis
Ono Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Ono Pharmaceutical Co., Ltd. - Pipeline Products By Target
Ono Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Ono Pharmaceutical Co., Ltd. – Pipeline Products by Molecule Type
Ono Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Ono Pharmaceutical Co., Ltd. - Dormant Projects
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Arocyte
Cereact
ONO-2333Ms
ONO-5129
ONO-6818
Ono Pharmaceutical Co., Ltd. – Company Statement
Ono Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jul 29, 2010: Ono Submits NDA In Japan For Onoact 50 For Injection
Feb 28, 2005: Development Status of ONO-2506 for Injection/PROGLIA outside Japan and Development Plan of Compounds in-licensed from Merck in Japan.
May 27, 2003: Announcement Of Termination Of Exclusive License Agreement On Sivelestat (Elaspol 100 For Injection) With Eli Lilly And Company
May 26, 2005: Development Status of ONO-2506 for Injection/PROGLIA
Sep 24, 2010: Ono Files Application In Japan For Intravenous Antiemetic Selective Neurokinin-1 Receptor Antagonist, Fosaprepitant
Apr 22, 2011: Ono Pharmaceutical Receives Approval For Rivastach Patch For Treatment Of Alzheimer’s Disease
Jun 21, 2000: Ono And Lilly Signed A License Agreement On The Worldwide Development And Marketing Of A Novel Therapeutic Drug For Acute Lung Injury
Dec 20, 2007: Nissan Chemical Industries Announces License Agreement With Ono Pharmaceutical For New Therapeutic Agent For Thrombocytopenia
Jul 19, 2011: Ono Pharmaceutical Launces Rivastach Patch For Treatment Of Dementia Of Alzheimer’s Type
Sep 15, 2011: Astellas And Ono Pharmaceutical To Launch RECALBON Tablets In Japan
Nov 10, 2004: Merck Licenses Stroke Drug from Ono
Nov 10, 2004: Ono and Merck in Product Licensing Arrangements
Sep 10, 2010: Ono And Astellas Submit Market Authorization Application For RECALBON Tablets For Osteoporosis In Japan
Jun 08, 2009: Progenics Announces Initiation Of RELISTOR Clinical Trials In Japan By Ono Pharmaceutical
Apr 05, 2011: Ono Pharmaceutical Launches Orally Disintegrating Tablet Of Staybla Tablets 0.1mg For Overactive Bladder
Jul 01, 2011: Ono And Astellas Announce Approval For RECALBON Tablets 50mg/Bonoteo Tablets 50mg In Japan
Mar 01, 2010: NDA Submission In Japan For Rivastigmine Patch, The First Transdermal Patch Therapy To Treat Alzheimer’s Disease
Financial Deals Landscape
Ono Pharmaceutical Co., Ltd., Deals Summary
Ono Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Progenra Enters Into Research Agreement With Ono Pharmaceutical
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharmaceutical
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharmaceutical For ORENCIA
Ono Pharmaceutical Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex
Xention Extends Collaboration With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Co-Development Agreement With BioFocus
BioSeek Enters Into Drug Discovery Collaboration With Ono Pharmaceutical
Evotec Extends Research Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Research Agreement With Xention
Ono Pharmaceutical Enters Into Drug Discovery Agreement With Evotec
Ono Pharmaceutical Enters Into New Co-Development Agreement With Locus Pharmaceuticals
BioFocus Enters Into Co-Development Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Co-Development Agreement With Locus Pharmaceuticals
Ono Pharmaceutical Enters Into Research Agreement With Medarex
Ono Pharmaceutical Enters Into Agreement With Dainippon Sumitomo Pharma
Ono Pharmaceutical Enters Into Co-Development Agreement With Array BioPharma
Discovery Partners Enters Into Collaboration With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Research Agreement With Medarex
Licensing Agreements
Ono Pharmaceutical Enters Into Licensing Agreement With CeNeS Pharmaceuticals
Merck Serono Enters Into Licensing Agreement With Ono Pharmaceutical For ONO-4641
Merck Serono Enters Into Licensing Agreement With Ono Pharmaceutical For Stimuvax
Ono Pharmaceutical Enters Into Licensing Agreement With KAI Pharmaceuticals For KAI-4169
Ono Pharmaceutical Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine
Ono Pharmaceutical Enters Into Licensing Agreement With OncoTherapy
Onyx Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical For Carfilzomib And ONX 0912
Concordia Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical For Salirasib
Tioga Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
Ono Pharmaceutical Enters Into Licensing Agreement With Nissan Chemical Industries
Ono Pharmaceutical Enters Into Licensing Agreement With Sapphire Therapeutics
Ono Pharmaceutical Enters Into Licensing Agreement With Santen Pharmaceutical
Ono Pharmaceutical Enters Into Agreement With Novartis Pharma
Ono Pharmaceutical Enters Into Licensing Agreement With Merck
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Ono Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Ono Pharmaceutical Co., Ltd. – Filed, H2 2011
Ono Pharmaceutical Co., Ltd. – Phase III, H2 2011
Ono Pharmaceutical Co., Ltd. - Phase II, H2 2011
Ono Pharmaceutical Co., Ltd. - Phase I, H2 2011
Ono Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, H2 2011
Ono Pharmaceutical Co., Ltd. - Pipeline By Target, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline By Molecule Type, H2 2011
Ono Pharmaceutical Co., Ltd. – Recent Pipeline Updates, H2 2011
Ono Pharmaceutical Co., Ltd. - Dormant Developmental Projects, 2010
Ono Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2010
Ono Pharmaceutical Co., Ltd., Other Locations
Ono Pharmaceutical Co., Ltd., Subsidiaries
Ono Pharmaceutical Co., Ltd., Deals Summary
Progenra Enters Into Research Agreement With Ono Pharmaceutical
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharmaceutical
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharmaceutical For ORENCIA
Ono Pharmaceutical Enters Into Agreement With Dainippon Sumitomo For Limaprost Alfadex
Xention Extends Collaboration With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Co-Development Agreement With BioFocus
BioSeek Enters Into Drug Discovery Collaboration With Ono Pharmaceutical
Evotec Extends Research Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Research Agreement With Xention
Ono Pharmaceutical Enters Into Drug Discovery Agreement With Evotec
Ono Pharmaceutical Enters Into New Co-Development Agreement With Locus Pharmaceuticals
BioFocus Enters Into Co-Development Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Co-Development Agreement With Locus Pharmaceuticals
Ono Pharmaceutical Enters Into Research Agreement With Medarex
Ono Pharmaceutical Enters Into Agreement With Dainippon Sumitomo Pharma
Ono Pharmaceutical Enters Into Co-Development Agreement With Array BioPharma
Discovery Partners Enters Into Collaboration With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Research Agreement With Medarex
Ono Pharmaceutical Enters Into Licensing Agreement With CeNeS Pharmaceuticals
Merck Serono Enters Into Licensing Agreement With Ono Pharmaceutical For ONO-4641
Merck Serono Enters Into Licensing Agreement With Ono Pharmaceutical For Stimuvax
Ono Pharmaceutical Enters Into Licensing Agreement With KAI Pharmaceuticals For KAI-4169
Ono Pharmaceutical Enters Into Licensing Agreement With Les Laboratoires Servier For Ivabradine
Ono Pharmaceutical Enters Into Licensing Agreement With OncoTherapy
Onyx Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical For Carfilzomib And ONX 0912
Concordia Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical For Salirasib
Tioga Pharmaceuticals Enters Into Licensing Agreement With Ono Pharmaceutical
Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
Ono Pharmaceutical Enters Into Licensing Agreement With Nissan Chemical Industries
Ono Pharmaceutical Enters Into Licensing Agreement With Sapphire Therapeutics
Ono Pharmaceutical Enters Into Licensing Agreement With Santen Pharmaceutical
Ono Pharmaceutical Enters Into Agreement With Novartis Pharma
Ono Pharmaceutical Enters Into Licensing Agreement With Merck

List of Figures
Ono Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, H2 2011
Ono Pharmaceutical Co., Ltd. - Pipeline By Target, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Ono Pharmaceutical Co., Ltd. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Abbott Laboratories - IT Sales Opportunities - 2009
• Company Study of Shanghai Kingstar Winning Software Co., Ltd., 2011
• Company Study of Shanghai Kingstar Winning Software Co., Ltd., 2011
• Citizen Holdings Co., Ltd.
• SANYO Electric Co., Ltd.
• Tokyo Seimitsu Co Ltd
• Furukawa Co., Ltd.
• China Stock Listed Electronic Components Companies Report , 2006-2007
• China Stock Listed Electronic Components Companies Report , 2006-2007
• Apollo Hospitals Enterprise Limited - IT Sales Opportunities - 2009